Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM1F Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT05746897Phase 1Recruiting
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NM1F in solid tumor, ovarian cancer, melanoma and 2 more (2 arms), sponsored by Hefei TG ImmunoPharma Co., Ltd. Primary endpoints: Dose-limiting Toxicity at 21 days, Recommended Phase 2 Dose at 3 years and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
NM1F
03
Conditions
solid tumorovarian cancermelanomatriple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05746897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746897.